Publication:
Pazopanib-Induced Reversible Left Ventricular Systolic Dysfunction

0
0

Issued Date

2022

Resource Type

Article

Language

eng

File Type

application/pdf

ISSN

1252208

DOI

10.35755/jmedassocthai.2022.S01.00030

Rights Holder(s)

Scopus

Bibliographic Citation

Journal of the Medical Association of Thailand. Vol 105, No. (2022), p.S130-S133

Suggested Citation

Roongsangmanoon W., Wattanawinitchai K., Charonpongsuntorn C., Chonmaitree P., Wongsoasup A., Rattanajaruskul N., Angkananard T. Pazopanib-Induced Reversible Left Ventricular Systolic Dysfunction. Journal of the Medical Association of Thailand. Vol 105, No. (2022), p.S130-S133. doi:10.35755/jmedassocthai.2022.S01.00030 Retrieved from: https://hdl.handle.net/20.500.14740/10291

Title

Pazopanib-Induced Reversible Left Ventricular Systolic Dysfunction

Author(s)

Roongsangmanoon W.
 Wattanawinitchai K.
 Charonpongsuntorn C.
 Chonmaitree P.
 Wongsoasup A.
 Rattanajaruskul N.
 Angkananard T.

Abstract

Pazopanib is a tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. The authors describe a patient with advanced renal cell carcinoma who developed severe hypertension and severe left ventricular systolic dysfunction after starting pazopanib therapy with subsequent recovery of left ventricular ejection fraction upon treatment interruption. © JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND

Subject(s)

Bisoprolol
 Furosemide
 Hydralazine
 Isosorbide dinitrate
 Losartan
 Pazopanib
 Protein tyrosine kinase inhibitor
 Sunitinib
 Troponin
 Valsartan
 Aged

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/10291

Collections

Scopus: Year 2022

Endorsement

Review

Supplemented By

Referenced By